AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06598462
Drug: Solrikitug High Dose
RxNorm normalized name: high-density polyethylene
DrugBank: Solrikitug (DB19301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solrikitug high dose subcutaneous injection
Trial: NCT05230368
Drug: Decitabine cycle 1
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine administration (5mg/m²) at days 1, 2, 3
Trial: NCT05230368
Drug: Romidepsin cycle 1
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin administration (5mg/m²) at days 4, 11, 18
Trial: NCT05230368
Drug: Decitabine cycle 2
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine administration (5mg/m²) at days 35, 36, 37
Trial: NCT05230368
Drug: Romidepsin cycle 2
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin administration (5mg/m²) at days 38, 45, 52
Trial: NCT05230368
Drug: Decitabine cycle 3
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine administration (5mg/m²) at days 70, 71, 72
Trial: NCT05230368
Drug: Romidepsin cycle 3
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin administration (5mg/m²) at days 73, 80, 87
Trial: NCT05230368
Drug: Decitabine cycle 4
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine administration (5mg/m²) at days 105, 106, 107
Trial: NCT05230368
Drug: Romidepsin cycle 4
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin administration (5mg/m²) at days 108, 115, 122
Trial: NCT05184062
Drug: 600 mg AZD7442 IV
RxNorm normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
Trial: NCT06068881
Drug: Tazverik (Tazemetostat)
RxNorm normalized name: Tazverik
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Tablet
Trial: NCT05797831
Drug: Navtemadlin
RxNorm normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
Trial: NCT05797831
Drug: Navtemadlin Placebo
DrugBank: Navtemadlin (DB15299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
Trial: NCT06678269
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The dose escalation portion of the study, a 3+3 design will be used. Once the MTD of Abemaciclib is reached, the phase Ib expansion portion will enroll up to 10 additional patients also requiring palliation to bone metastases
Trial: NCT04791319
Drug: Bermekimab
RxNorm normalized name: Bermekimab
DrugBank: Bermekimab (DB14947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bermekimab will be administered subcutaneously.
Trial: NCT04791319
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupilumab will be administered subcutaneously.
Trial: NCT04891770
Drug: Tenofovir Alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as film-coated oral tablets
Trial: NCT04891770
Drug: VIR-2218
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a sub-cutaneous (SC) injection
Trial: NCT04891770
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT04891770
Drug: Selgantolimod
RxNorm normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as film-coated oral tablets
Trial: NCT04959240
Drug: Velmanase Alfa
RxNorm normalized name: Velmanase alfa
DrugBank: Velmanase alfa (DB12374)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04919499
Drug: BI 765128
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 765128
Trial: NCT06697431
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients who fulfill the eligibility criteria a will be randomized 1:1 to receive either~1. IVIG 2g/kg administered in 10-12 hours as per local standard of care (standard treatment) OR~2. Anakinra 2mg/kg intravenously, max 100 mg/dose 4 times/day (investigational treatment)~Patients showing fever, between 36 hours and 72 hours from the end of first line treatment will be considered failures. Failures from the investigational treatment arm will receive a dose of IVIG and they will drop from the study.~Children who remained afebrile between the 36th and 72nd hour will be considered as responders, and they will proceed into the study.~Patients in the standard treatment arm will continue ancillary treatment and follow-up .~Patients in the investigational treatment arm will enter the tapering phase.
Trial: NCT06696105
Drug: Resin infiltration
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icon® resin infiltration (DMG America, Englewood, NJ, US) technique utilizes light-cured hydrophilic and low viscosity resins that can permeate WSL subsurface micropores. Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release . Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
Trial: NCT06696105
Drug: Vanish XT varnish (resin modified glass ionomer restoration)
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release. Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
Trial: NCT02137525
Drug: Morphine 6 mg
RxNorm normalized name: apomorphine 6 MG
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion - delivering morphine 6 mg
Trial: NCT04987762
Drug: Adhansia XR
RxNorm normalized name: Adhansia XR
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)
Trial: NCT05031546
Drug: Difelikefalin
RxNorm normalized name: DIFELIKEFALIN
DrugBank: Difelikefalin (DB11938)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)
Trial: NCT06056687
Drug: Alpha Lipoic Acid 600 MG Oral Tablet
RxNorm normalized name: alpha lipoic acid 600 mg ORAL TABLET
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha Lipoic Acid 600 MG Oral Tablet once daily
Trial: NCT05265923
Drug: CM310
RxNorm normalized name: Immunoglobulin G4 [227-proline], anti-(human interleukin 4 receptor subunit α) (human-Mus musculus monoclonal CM310 γ4-chain), disulfide with human-Mus musculus monoclonal CM310 κ-chain, dimer
DrugBank: Stapokibart (DB18990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-4Rα monoclonal antibody
Trial: NCT06252103
Drug: Ferrous Gluconate 300 MG
RxNorm normalized name: ferrous gluconate 300 MG
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iron salt one tab 300 mg contain 35 mg of elemental iron given 2 doses 600 mg per day
Trial: NCT06252103
Drug: ferrous gluconate with lactoferrin
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin is a glycoprotein from the transferrin family consist of 691 amino acids,Lactoferrin is a protein found in cow milk and human milk
Trial: NCT05320705
Drug: Intra Operative Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
Trial: NCT04507919
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150 mg
Trial: NCT04507919
Drug: Trametininb
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.0 mg
Trial: NCT06566326
Drug: Propofol and ketamine
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received IV sedation using prepared mixture of propofol and ketamine in ratio (4:1). It is prepared by mixing 0.8 mg/kg propofol with 0.2 mg/kg ketamine (4:1) in an IV bolus, followed by half of the initial dose every 3 minutes as needed for sedation. The desired level of sedation was achieved (more than score 4) using Modified Ramsay sedation score) before allowing endoscopiest to start the procedure, then the score was assessed every 3 minutes before giving of top up doses of ketofol 4:1 (half of the initial dose) if needed, then the range and median of modified Ramsay sedation score was calculated.
Trial: NCT06699472
Drug: Trilaciclib Injection [Cosela]
RxNorm normalized name: trilaciclib Injection [Cosela]
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trilaciclib, intravenous infusion, 240 mg/m2, administered following chemotherapy (2 hours after completion of vincristine administration and within 4 hours before administration of other chemotherapy drugs)
Trial: NCT00000672
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06699576
Drug: HS-20093
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-20093: administered as an IV infusion
Trial: NCT06699576
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib: 12mg once daily (QD) orally
Trial: NCT05063357
Drug: 131I-Omburtamab
RxNorm normalized name: 131I-omburtamab
DrugBank: Omburtamab I-131 (DB17124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).
Trial: NCT06699576
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin: administered as an IV infusion
Trial: NCT05945615
Drug: Oxymetazoline 0.1% (Pf) Oph Soln Ud
RxNorm normalized name: OXYMETAZOLINE 0.1% (PF) OPH SOLN UD
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline was initially developed in 1961. It is a direct sympathomimetic, binding directly to alpha-1 and alpha-2 receptors. Currently, it is used as a nasal decongestant, in the treatment of epistaxis, and as a topical treatment for rosacea. Previously, an ophthalmic formulation was used to treat eye redness and irritation as it is FDA approved for the treatment of acquired blepharoptosis. However, this product line was discontinued when in July of 2020, oxymetazoline received Food and Drug Administration approval for treatment of cosmetic blepharoptosis.~In the treatment of blepharoptosis, oxymetazoline acts on the superior tarsal muscle, Müller's muscle, to elevate the eyelid. The superior tarsal muscle is a sympathetically innervated muscle that is partially responsible for elevating the eyelid. Previous cosmetic studies have shown oxymetazoline can serve as an adjunct to botulinum toxin in patients with acquired blepharoptosis.
Trial: NCT06699576
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab: administered as an IV infusion
Trial: NCT06698484
Drug: CAR-T cells
RxNorm normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2×10\^6 CAR T cells/kg
Trial: NCT05514405
Drug: Remimazolam (Byfavo)
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam is continuously infused based on bispectral index (within 40-60).
Trial: NCT05514405
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol is continuously infused based on bispectral index (within 40-60).
Trial: NCT05326347
Drug: OPC-34712FUM/ Brexpiprazole fumarate
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.
Trial: NCT00000753
Drug: Atevirdine mesylate
RxNorm normalized name: mesylate
DrugBank: Atevirdine (DB12264)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000753
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000753
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000753
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03867487
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
Trial: NCT00000743
Drug: Alvircept sudotox
RxNorm normalized name: Alvircept sudotox
DrugBank: Alvircept sudotox (DB12786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000743
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02229175
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injections of antibodies inhibiting vascular endothelial growth factor
Trial: NCT00269802
Drug: OROS methylphenidate HCl
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00269802
Drug: Ritalin
RxNorm normalized name: Ritalin
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06627309
Drug: Bortezomib (drug)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib is administered subcutaneously. The dosage range from 0.7 to 1.3 mg/m2 on days 1, 8, 15, and 22 of each cycle, for a maximum of 6 cycles
Trial: NCT06627309
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone is administered intravenously at a dose of 40 mg weekly for each cycle, for a maximum of 6 cycles. For patients over 70 years of age or with severe edema, heart failure, or uncontrolled diabetes mellitus, dexamethasone can be administered at a dose of 10-20 mg per week.
Trial: NCT06258720
Drug: Lu AF82422
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AF82422 solution for intravenous infusion
Trial: NCT05861128
Drug: Jaktinib
RxNorm normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks
Trial: NCT05601401
Drug: RC48-ADC
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RC48-ADC 2.0 mg/kg IV every 14 days
Trial: NCT06411730
Drug: BMS-986368
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05322148
Drug: Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.
Trial: NCT05606757
Drug: BOTOX Dose A
RxNorm normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection; intramuscular
Trial: NCT05606757
Drug: Placebo for BOTOX
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Placebo
Trial: NCT05606757
Drug: BOTOX Dose B
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection; intramuscular
Trial: NCT05606757
Drug: BOTOX Dose C
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection; intramuscular
Trial: NCT06380699
Drug: Human Urinary Kallidinogenase
RxNorm normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tissue kallikrein-1
Trial: NCT06356883
Drug: IA Carboplatin + IA Caelyx
RxNorm normalized name: magnesium aluminum silicate type Ia
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarterial infusion of carboplatin combined with liposomal doxorubicin
Trial: NCT06356883
Drug: IA Carboplatin + IA Etoposide Phosphate
RxNorm normalized name: magnesium aluminum silicate type Ia
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarterial infusion of carboplatin combined with etoposide phosphate
Trial: NCT01487044
Drug: Macugen (Pegaptanib Sodium)
RxNorm normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe has a needle attachment at allows for a 30-guage need to be fixed to the syringe prior to injection. The stoppered syringe is packaged in a foil pouch. The drug product is preservative-free and intended for single use by intravitreous injection only.
Trial: NCT00416858
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05421338
Drug: BI 456906 (C-14)
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 456906 (C-14)
Trial: NCT05131464
Drug: CM310
RxNorm normalized name: Immunoglobulin G4 [227-proline], anti-(human interleukin 4 receptor subunit α) (human-Mus musculus monoclonal CM310 γ4-chain), disulfide with human-Mus musculus monoclonal CM310 κ-chain, dimer
DrugBank: Stapokibart (DB18990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM310, 300 mg/2 mL, SC, every 2 weeks
Trial: NCT03865615
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal oxytocin 40IU/mL
Trial: NCT05347758
Drug: HRS-7535
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: HRS-7535
Trial: NCT04931823
Drug: CPO-100
RxNorm normalized name: CPO-107
DrugBank: CPO-107 (DB18492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel albumin-bound
Trial: NCT05025813
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delivery of neo-adjuvant Pembrolizumab
Trial: NCT04997798
Drug: Trastuzumab Pyrotinib Exemestane Dalpiciclib
RxNorm normalized name: Exemestane
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early triple positive breast cancer patients receive combination regimen of Dalpiciclib in Combination With Exemestane and Trastuzumab plus pyrotinib
Trial: NCT05980208
Drug: Inetetamab
RxNorm normalized name: Inetetamab
DrugBank: Inetetamab (DB17457)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inetetamab-based treatment for first-line treatment of HER2-positive MBC